HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and m…

HanchorBio and WuXi Biologics Form Fusion Protein Pipeline Partnership

CRDMO WuXi Biologics and HanchorBio, a clinical-stage biotech company focusing on immunotherapies for oncology and autoimmune diseases, signed a collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline. HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen celebrate the signing of the strategic partnership agreement. [Hanc…